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Abstract
It is increasingly clear that complex networks of relationships between genes and/or proteins
govern neoplastic processes. Our understanding of these networks is expanded by the use of
functional genomic and proteomic approaches in addition to computational modeling.
Concurrently, whole-genome association scans and mutational screens of cancer genomes identify
novel cancer genes. Together, these analyses have vastly increased our knowledge of cancer, in
terms of both "part lists" and their functional associations. However, genetic interactions have
hitherto only been studied in depth in model organisms and remain largely unknown for human
systems. Here, we discuss the importance and potential benefits of identifying genetic interactions
at the human genome level for creating a better understanding of cancer susceptibility and
progression and developing novel effective anticancer therapies. We examine gene expression
profiles in the presence and absence of co-amplification of the 8q24 and 20q13 chromosomal
regions in breast tumors to illustrate the molecular consequences and complexity of genetic
interactions and their role in tumorigenesis. Finally, we highlight current strategies for targeting
tumor dependencies and outline potential matrix screening designs for uncovering molecular
vulnerabilities in cancer cells.
Background
Most of the current knowledge of cancer susceptibility,
progression and treatment has been generated by tradi-
tional approaches, in which small numbers of genes or
proteins are characterized in depth to study the molecular
mechanisms of neoplastic processes. With the advent of
large-scale functional genomic and proteomic ("omic")
methodologies, additional mechanistic insights into neo-
plasia have been uncovered. Whole-genome association
studies for cancer risk variants and somatic mutation
screening projects have completed their initial phases and
will provide the "part lists" of cancer genes, both at the
germline [1] and the somatic levels [2]. Transcript analy-
ses have identified expression profiles that provide accu-
rate prognoses for cancer patients [3]. Systematic mapping
of protein-protein interactions is currently being carried
out in what are referred to as 'interactome' mapping
projects. This research will elucidate the wiring diagram of
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protein associations in cells [4,5]. These types of genes
and/or protein (gene/protein) functional relationships
can be modeled together to provide better understanding
and predict molecular mechanisms of neoplasia [6-10].
Genetic interactions are identified when the action of one
gene measured through a molecular, cellular or organism
phenotype is modified by one or more other genes. They
provide insight into biological processes that are comple-
mentary but which frequently do not overlap with other
types of gene/protein associations [11]. To date, genetic
interactions remain largely unknown on a large scale in
human systems. Previous reviews and assays gave excel-
lent descriptions of the role of genetic interactions in
understanding phenotypic variability [12-14]. Here, we
focus our discussion on the potential of studying human
genetic interactions as a means of not only better under-
standing cancer susceptibility and progression but also,
and most importantly, developing novel anticancer treat-
ments.
Discussion
A step forward in cancer research
The use of 'model organisms' (i.e. species that meet the
criteria of being representative of particular organisms or
cellular behaviour) has played a prominent role in all
aspects of biology. Since the first description of the com-
plete sequence of an eukaryotic genome, the yeast Saccha-
romyces cerevisiae [15], the use of model organisms has
grown with the development of high-throughput screen-
ings for large-scale genomic and proteomic investigations
[16]. Using these technologies and models, researchers
have been able to acquire a greater understanding of how
most, if not all, genes/proteins act coordinately to deter-
mine the properties of an organelle, cell or organism [8].
This "systems-level" research is also being used to deci-
pher complex networks of molecular relationships in
human systems, in healthy or normal conditions and
their perturbation in disease or unconventional molecu-
larly – or environmentally-modified conditions.
Of the possible gene-to-gene relationships in complex
networks, genetic interactions were first mapped on a
large scale in yeast [17]. These studies identified "synthetic
lethal" interactions that occur when the combination of
two gene deletions causes cell death whereas neither dele-
tion is lethal by itself (i.e. non-essential genes). In addi-
tion to "synthesis", interactions can also be revealed by
"epistasis", which is commonly used to define "genetic
interactions" in statistical terms and describes the devia-
tion from additivity for a quantitative phenotype by the
effect of genetic variants or mutations at different loci [18-
20]. Many models of interactions between different loci
have been identified, including the combination of
"aggravating" or agonistic and "alleviating" or buffering
relationships [21,22].
Given the complexity of genetic interaction relationships,
understanding the topology of genetic interaction net-
works is crucial for establishing genotype-phenotype cor-
relations. This knowledge has clear implications in the
study of certain aspects of common, "complex" or non-
Mendelian diseases, such as the incidence of cancer in the
general population, where the sum of minor gene effects
contributes to the risk [23]. In addition to germline cancer
risk, the mapping of genetic interactions in humans may
also provide information on cancer progression and treat-
ment, due to the large number of genes involved and the
complexity of pathological phenotypes. Lessons learned
from the study of genetic interactions in model organisms
could be applied in defining hitherto unimaginable
approaches for studying complex biological aspects of
neoplastic processes.
Lessons from model organisms
The study of genetic interactions has been typically used
in the annotation of signaling or metabolic pathways and
protein complexes as a means of inferring the logical
order of their components and examining pathway cross-
talk [24]. A remarkable finding made in early systematic
deletion analysis studies of yeast indicated that most
eukaryotic genes are dispensable for viability. Only ~20%
of Saccharomyces cerevisiae genes are essential for haploid
cells grown in standard laboratory conditions [25,26].
Topological analysis of the yeast genetic interaction net-
work has revealed the importance of gene interactions in
phenotype modelling. More than 30 interactions on aver-
age were identified for non-essential genes and five-fold
more for essential genes [17,27]. Accordingly, a recent
estimate predicts ~200,000 synthetic lethal interactions in
the global yeast genetic network [12]. When extrapolated
to humans, these figures result in a vast number of genetic
interactions with a specific phenotype potentially influ-
enced by hundreds of different gene combinations. This
estimate does not include combinations of more than two
genes, which remain difficult to calculate at this stage.
These predictions for phenotype determinants in humans
clearly reveal the need for large-scale genetic interaction
projects to provide more in-depth knowledge of complex
diseases. Beyond the examination of single or small num-
bers of genes, systems-level analyses of model organisms
have also uncovered the complex structure of genetic
interaction networks. Epistasis extends beyond individual
genes to clusters or modules of functionally related genes
[28]. At this systems-level, perturbing one functional
module can have aggravating or alleviating consequences
on another.Molecular Cancer 2008, 7:4 http://www.molecular-cancer.com/content/7/1/4
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Further advances could potentially be made through com-
putational prediction of human genetic interactions using
different types of experimentally generated molecular
interactions. However, the modest overlap observed
between experimentally identified genetic interactions
and protein-protein interactions in yeast suggests that any
predictions will render largely incomplete data [11,29-
31]. Furthermore, given a pair of genes and their corre-
sponding gene products, calculations in yeast give approx-
imately four times more genetic interactions than protein-
protein interactions. Finally, using orthologs to transfer
genetic interactions across species may show even lower
confidence than for protein-protein interologs [32], due
to the observed complexity of the relationships between
apparently molecularly unrelated signaling or metabolic
pathways [28,33]. Taken together, computational predic-
tions of human genetic interactions may provide lists of
candidate gene pairs but, until further advances are made,
they will require extensive experimental validation.
Systematic identification of genetic interactions in a mul-
ticellular organism has been described in a recent study by
Lehner et al. [34]. The authors identified genetic interac-
tions in Caenorhabditis elegans using the RNA interference
(RNAi) method, which entails analyzing hypomorphic
alleles rather than complete transcript depletion, which is
the preferred methodology in the majority of yeast stud-
ies. Lehner et al. [34] highlighted the global relevance to
phenotype modeling of genetic interactions between
components of the same pathway, rather than interac-
tions between components of different pathways. This
study also anticipated the methodological problems and
interpretational caveats that may appear when performing
large-scale screening of genetic interactions in humans.
Human studies require vast amounts of effort, the preven-
tion of false positives in large-scale RNAi screens [35], and
the incorporation of multiple designs to account for dif-
ferent cellular models and conditions [14]. Nevertheless,
we believe that they can have an enormous impact on our
knowledge of cancer.
Genetic interactions and cancer susceptibility
Projects such as the Cancer Genetic Markers of Suscepti-
bility (CGEMS) initiative and the work carried out by
Cancer Research UK within an international consortium
are currently providing the preliminary partial lists of low-
penetrance genetic variants for risk of different cancer
types in the general population [36,37]. Initial analyses of
this data have used a whole-genome approach to identify
the main effects of individual variants. However, earlier
studies based on candidate-gene approaches had already
highlighted the existence of interactions between variants
in different genes influencing cancer susceptibility [38]. It
is now thought that the analysis of large series of individ-
uals, together with the development of novel statistical
approaches, will facilitate the assessment of millions of
variant combinations which will, in turn, enable us to elu-
cidate the impact of genetic interactions in cancer suscep-
tibility [39]. Promising analyses based on simulations and
empirical data have demonstrated that the likelihood of
detecting significant associations increases when epistasis
is taken into account [39-41].
The drawback of analyses taking into account epistasis is
the trade-off between statistical power and false discovery
rate. Current whole genome association studies consider
over 500,000 single nucleotide polymorphisms, and P
values need to be under 10-7 to account for multiple com-
parisons. Since low-penetrance alleles provide modest
increases in risk, in the range of 20–30%, the sample sizes
needed to detect main effects are in the range of 2,000 to
5,000 cases and a similar number of controls. When the
aim is to detect gene interactions, the required number of
tests increases to 2.5 × 1011 and the P value should be cor-
rected to 2 × 10-13. The sample sizes needed for these sig-
nificance levels are larger, but currently feasible – in the
range of 6,000 to 15,000 cases for variants with high fre-
quencies (20–40%) [41,42]. Novel statistical approaches
have been proposed which reduce the dimensionality of
the problem of searching for relevant gene interactions.
The multifactor dimensionality reduction (MDR) method
has been successfully applied to limited-scale scenarios
[38,43,44]. Other promising proposals include the
restricted partition method (RPM) [45] and combinato-
rial searching methods (CSM) [46]. Nevertheless, given
the large number of expected false positive genetic interac-
tions that will be proposed following analysis of whole-
genome association studies, it will be necessary to carry
out extensive validation in multiple populations and bio-
logical models based on the experimental identification
of genetic interactions [47].
Genetic interactions and cancer progression
Cancer arises from the consecutive acquisition of genetic
alterations that, in general, produce the loss of function or
transcriptional down-regulation of tumor suppressor
genes and the activation or transcriptional up-regulation
of oncogenes [48]. Downstream of the genetic alterations
in tumorigenesis we find expression changes in many
genes, which lead to abnormal regulation of biological
processes such as the cell cycle and apoptosis [9,49]. Con-
sequently, it is thought that genetic and molecular altera-
tions promote tumorigenesis in the context of highly
connected and regulated gene/protein networks [7,8,50].
Thus, the progression from normal epithelium to benign
dysplasia to metastases is relatively well characterized for
some cancer types and highlights a specific molecular pro-
gram [51]. The importance of studying genetic interac-
tions between tumor suppressor genes, such as the
retinoblastoma RB1 gene, and oncogenes, such as the RASMolecular Cancer 2008, 7:4 http://www.molecular-cancer.com/content/7/1/4
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family, was established in earlier works that provided fun-
damental insights into the mechanisms of tumorigenesis
and metastasis [52-54].
Knowledge of the sequence of genetic alterations that con-
tribute to the neoplastic process could be used to target
cancer cells according to the concept of synthetic lethality.
Thus, it may be possible to reveal cancer genetic altera-
tions useful for identifying genetic interactions by exam-
ining the profiles of somatic mutations, genomic
alterations or gene expression changes in large series of
tumors (Fig. 1). Under this hypothesis, the examination
of highly correlated profiles may help to detect strong
gene/protein dependencies in cancer cells. A greater
understanding of these dependencies may illuminate
mechanisms of carcinogenesis with insights into progno-
sis. Differences in biological meanings could also be
extrapolated from positive versus negative correlations,
implying molecular dependencies in different directions.
Research into this hypothesis will be aided by the charac-
terization at different genomic levels of large series of
tumors. The Cancer Genome Project at the Sanger Insti-
tute has sequenced hundreds of human genes in tumors,
tissues and cell lines [55,56]. Recent results obtained by
other groups have demonstrated that oncogene activation
in tumors is usually mutually exclusive. However, it has
also been shown that some co-occurring mutations may
reflect dependencies that are critical for neoplasia [57].
The identification of these types of neoplastic-specific
functional dependencies could improve prognosis predic-
tion and tumor classification, while targeting these
dependencies may enhance therapeutic efficacy.
Empirical analysis of genetic interactions acting on tumor 
phenotypes
The integrative analysis of cancer molecular data sheds
light on the mechanisms of neoplasia [6,10,58-60]. As
discussed above, as large series of tumors and cell lines are
characterized we will gradually be able to detect molecular
dependencies and the ways in which they influence cancer
progression. Co-amplification of specific genomic regions
in breast tumors has been suggested and may represent
cancer gene interactions between oncogenes that promote
neoplasia. Specifically, co-amplification of the 8q24 and
20q13 regions may target the c-MYC  and  ZNF217  or
BCAS1 proto-oncogenes, respectively [60].
To assess the 8q24/20q13 interaction, we evaluated
molecular phenotypes such as transcript levels and co-
expression between known breast cancer tumor suppres-
sors and oncogenes (Fig. 2). In the absence of emergent
genetic interactions, one may expect co-amplification of
8q24/20q13 to produce no relevant differences in gene
expression between breast tumors. However, differences
were observed beyond the simple additivity of expression
levels for many genes when comparing tumors showing
co-amplification with tumors showing single region
amplification or no amplification; for example, ERBB2
showed marked down-regulation in tumors with co-
amplification while the other tumors showed higher
expression levels (Fig. 2, middle panel). Molecular pheno-
typic alterations also produced increases or decreases in
correlation values of gene expression profiles, which are
comparable to the concepts of alleviating or aggravating
interactions; for example, a cluster of significant correla-
tions between ATM,EGFR,  ERBB2,  FGFR2  and  IKBKE
appeared to be stronger in tumors with only 8q24 ampli-
fications (Fig. 2, bottom panel). Portraits of expression
correlations were noticeably different between tumors
with different genomic alterations, to the extent that in co-
amplification there were no significant correlations. These
observations suggest differences in the molecular mecha-
nisms that promote cancer progression determined by
genetic interactions between cancer genes. This analysis is
limited by the sample size series and could be extended by
using multivariate analyses. Nevertheless, it illustrates the
potential usefulness of genetic interactions in understand-
ing tumor phenotypes.
Genetic interactions and cancer treatment
Robustness, which describes the ability of cells or organ-
isms to maintain viability and functionality despite (mul-
tiple) molecular perturbations, is a fundamental principle
in many biological systems [50,61-63]. Tumors are robust
systems par excellence and it is thought that robustness is
sustained by functional redundancy maintained by cell
heterogeneity and feedback transcriptional control mech-
anisms [50]. However, cancer robustness might be offset
by the extreme fragility of molecular networks. This idea
is the basis for the hypothesis that uncommon perturba-
tions of regular neoplastic processes would have dramatic
effects on cancer cells [64].
Information on the acquisition of germline and somatic
genetic alterations that contribute to neoplasia could then
be systematically analyzed to find the Achilles' heel of
cancer cells. The authors of a landmark study that paved
the way for this type of strategy discovered that cells defi-
cient in the breast cancer tumor suppressors BRCA1 and
BRCA2 are completely dependent on the normal activity
of the poly (ADP-ribose) polymerase family member 1
(PARP1) [65,66]. Inherited germline mutations in BRCA1
or BRCA2 genes confer high risk of breast and ovarian can-
cer, always accompanied by the somatic inactivation of
the remaining wild-type allele [67-69]. Consequently,
BRCA1/BRCA2-deficient tumor cells show genetic and
genomic instability due in part to impaired DNA damage
repair [70]. Against this background, depletion of PARP1
causes synthetic lethality due to severe defective homolo-
gous recombination necessary for regular DNA repairMolecular Cancer 2008, 7:4 http://www.molecular-cancer.com/content/7/1/4
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Correlation of genetic and genomic alterations and transcript profiles across hundreds of tumors may reveal gene/protein  functional dependencies that are useful for predicting genetic interactions of interest for cancer progression and anticancer  therapies Figure 1
Correlation of genetic and genomic alterations and transcript profiles across hundreds of tumors may reveal gene/protein 
functional dependencies that are useful for predicting genetic interactions of interest for cancer progression and anticancer 
therapies.Molecular Cancer 2008, 7:4 http://www.molecular-cancer.com/content/7/1/4
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Empirical analysis of genetic interactions acting on tumorigenesis Figure 2
Empirical analysis of genetic interactions acting on tumorigenesis. Pre-processed and normalized data were taken from Chin et 
al. [60]. White squares represent missing data. Log expression ratios are relative to tumors that do not show amplification at 
8q24 or 20q13. Average expression values are shown for each gene probe (not detailed) in each tumor set (8q24/20q13, 8q24 
or 20q13 amplification). Transcript correlations were calculated using the Pearson correlation coefficient and adjusted P values 
with a false discovery rate of 5%; only significant correlations with Q values < 0.05 are shown, except for the 8q24/20q13 co-
amplification set (dashed line; Q ~0.07).Molecular Cancer 2008, 7:4 http://www.molecular-cancer.com/content/7/1/4
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activity. Clinical trials using PARP1 inhibitors for breast
cancer, and other malignancies characterized by DNA
repair defects, now explore the potential of these interven-
tions.
The BRCA/PARP1 paradigm could be applied in different
terms to the observed tumor resistance to anticancer ther-
apies. An example of this would be the use of trastuzumab
for treating breast cancer with ERBB2  amplifications,
which represent ~25% of all cases [71]. Although these
tumors show great dependence on the HER-2 receptor for
growth and, as a result, frequently respond to trastuzu-
mab treatment, they almost always develop resistance.
Genetic interaction screens performed in the presence of
trastuzumab, or blocking HER-2, may reveal those genes
whose inactivation leads to synthetic lethality or sickness
pattern in breast cancer cells. Similar observations could
be made using imatinib and KIT gene mutations in gas-
trointestinal stromal tumors [72] or the Philadelphia
chromosome in chronic myeloid leukaemia [73]. A land-
mark study has recently demonstrated the usefulness of
the concept of synthetic lethality in identifying genes that,
when depleted, increase the sensitivity of cancer cells to
paclitaxel [74]. Another recent study has revealed the co-
activation of receptor tyrosine kinases as a mechanism
that allows cancer cells to survive single compound-based
treatments [75]. These observations further support the
use of combined target therapies based on the depletion
of selected genes to achieve superior therapeutic efficacy.
Genetic interactions screen designs
The fundamental aim of whole-genome systematic
screens of human genetic interactions is to reveal multiple
new anticancer therapy alternatives. Among various possi-
ble designs, these screens could be performed with a
matrix format and standard cancer cell lines and by
depleting genes using siRNAs or viral-packed shRNA con-
structs [76,77] (Fig. 3A). This approach would uncover a
cancer genetic interaction network without a priori
hypotheses concerning gene function, although current
knowledge of genetic alterations in cancer cell lines
should help to identify promising targets. This design
could be extended following the suggestion made by
Whitehurst et al. [74], in which sublethal concentrations
of anticancer agents are used.
Different interpretations of genetic interactions and their
applications will depend on whether the studied cell lines
or models represent dominant or recessive inherited can-
cer. Genetic interactions in dominant inherited cancer
Examples of matrix screens of genetic interactions of interest in studying cancer susceptibility, progression and treatment: (A)  Interactions are identified in standard cancer cell lines by depleting one gene at a time and through quantitation of emerging  phenotypes; (B) Interactions are identified between genes involved in the DNA repair processes, with quantitation of emerging  phenotypes highlighting repair subcategories; and (C) Interactions are revealed between known tumor suppressor genes and  oncogenes, with quantitation of emerging phenotypes highlighting different properties of the neoplastic process Figure 3
Examples of matrix screens of genetic interactions of interest in studying cancer susceptibility, progression and treatment: (A) 
Interactions are identified in standard cancer cell lines by depleting one gene at a time and through quantitation of emerging 
phenotypes; (B) Interactions are identified between genes involved in the DNA repair processes, with quantitation of emerging 
phenotypes highlighting repair subcategories; and (C) Interactions are revealed between known tumor suppressor genes and 
oncogenes, with quantitation of emerging phenotypes highlighting different properties of the neoplastic process.Molecular Cancer 2008, 7:4 http://www.molecular-cancer.com/content/7/1/4
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syndromes should specifically target tumor cells that, for
instance, lack both autosomal copies of a tumor suppres-
sor gene. When targeting these tumors with synthetic
lethal interventions, normal tissue and cells should
remain unaffected unless dose effects appear due to the
inactivation of a single allele in all cells. In recessive inher-
ited cancer syndromes such as Fanconi anemia, in which
all cells are inactivated for a specific gene, therapeutic tar-
geting with synthetic lethal disruption could potentially
act systemically, depending on cell-type specificities.
Designs for matrix screens of genetic interactions can also
be based on the current knowledge of common molecular
alterations in neoplasia (Fig. 3B). Many human genes
encoding for proteins involved in DNA damage repair
processes are mutated or epigenetically altered in cancer
cells [78]. Currently, there are ~150 human genes anno-
tated with DNA repair-related Gene Ontology terms [79].
Mapping interactions between these genes, including
somatic or germline mutations such as the mismatch
defects observed in colorectal tumors [80], is therefore
expected to be beneficial in different cancer types. Again,
the suggestion of Whitehurst et al. [74] could be applied
to the identification of interactions between DNA repair
genes by administering DNA-damaging agents at suble-
thal concentrations. In addition, many of these genes have
orthologs in model organisms that could be used to study
the conservation of synthetic lethality relationships and
their role in altering the cellular response to DNA damage.
Another possible matrix strategy that could be used to
identify new treatments consists of mapping interactions
between known tumor suppressor genes and oncogenes
(Fig. 3C). Unlike "passenger alterations", genetic altera-
tions that contribute to neoplasia occur in a specific com-
bination and order between tumor suppressor genes and
oncogenes [48,49]. This observation, otherwise fragility of
cancer genetic networks, could be useful in the identifica-
tion of therapeutic targets. This matrix design combines
the over-expression of tumor suppressors and the down-
regulation or depletion of oncogenes. The experimental
designs presented here are intended to stimulate interest
in the utility and importance of this type of gene relation-
ship in different areas of cancer research. We are confident
that future research can and will lead to more sophisti-
cated experimental designs for mapping genetic interac-
tions in human models, which will greatly enhance our
understanding of the molecular mechanisms of cancer.
Conclusion
Interactions between human genes are largely unknown.
From studies in model organisms, it is clear that genetic
interactions at the human genome-scale need to be iden-
tified in order to better understand common human dis-
eases, with cancer being the paradigm. The detection of
these interactions will be invaluable to our understanding
of cancer risk, by suggesting hypotheses concerning the
molecular mechanisms of susceptibility; of cancer pro-
gression, by revealing gene/protein functional dependen-
cies; and of cancer treatment, by providing the knowledge
required to develop new, efficient anticancer strategies.
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